References

  1. Lysaght MJ. Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol. 2002 Jan; 13(Suppl 1): S37-40. PubMed | Google Scholar

  2. Foley RN, Parfrey P, Samak MJ. Clinical epidemiology of cardiovascular disease in chronic renal failure. Am J Kidney Dis.1998 Nov; 32(5 Suppl 3): S112-9. Google Scholar

  3. Weiner DE, Tighiouart H, Amin MG, Stark PC et al. Chronic kidney disease as a risk factor for cardiovascular disease and all cause mortality: a pooled analysis of community based studies. J Am Soc Nephrol. 2004 May; 15(5): 1307-15. PubMed | Google Scholar

  4. Eghan BA, Amoako-Atta K, Kankam CA, Nsiah-Asare A. Survival pattern of hemodialysis patients in Kumasi, Ghana: a summary of forty patients initiated on hemodialysis at a new hemodialysis unit. Hemodial Int. 2009 Oct; 13(4): 467-471. PubMed | Google Scholar

  5. Muntner P, He J, Astor BC, Folsom AR, Coresh J. Traditional and non-traditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol 2005 Feb; 16(2): 529-538. Google Scholar

  6. Port FK, Hulbert-Shearon TE, Wolfe RA, Bloembergen WE et al. Pre-dialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kid Dis.1999 Mar; 33(3):507-17. Google Scholar

  7. Kasiske BL. Hyperlipidemia in patients with chronic renal disease. Am J Kid Dis. 1998 Nov; 32(Suppl 3): S142-56. PubMed | Google Scholar

  8. Thomas R, Kanso A, Sedor JR. Chronic Kidney Disease and its complications. Prim Care. 2008 Jun; 35(2): 329-44. PubMed | Google Scholar

  9. Parfrey PS (editor). Cardiac disease in chronic uraemia: uraemia related risk factors. Semin Dial.1999;20(14):997-1008. Google Scholar

  10. Shlipak MG, Fried LF, Cushman M, Manolio TA et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA. 2005 Apr 13; 293(14): 1737-1745. PubMed | Google Scholar

  11. Agarwal R, Light RP. Determinants and Prognostic Significance of Electrocardiographic Left Ventricular Hypertrophy Criteria in Chronic Kidney Disease. Clin J Am Soc Nephrol. 2011 Mar; 6(3): 528-36. PubMed | Google Scholar

  12. Stewart GA, Gansvoort RT, Mark PB, Rooney E et al. Electrocardiographic abnormalities and uraemic cardiomyopathy. Kidney Int. 2005 Jan; 67(1): 217-26. Google Scholar

  13. Chijioke A, Makusidi AM, Kolo PM. Electrocardiographic abnormalities among dialysis naïve chronic kidney patients in Ilorin, Nigeria. Ann Afr Med. 2012 Jan-Mar; 11(1): 21-6. PubMed | Google Scholar

  14. Nwankwo EA, Ummate I, Wudiri W. Prevalence of electrocardiographic left ventricular hypertrophy among incident dialysis patients in Maiduguiri, Nigeria. Res J Medicine and Med Sci. 2007; 2(1): 1-4. Google Scholar

  15. Foley RN, Parfrey PS, Harnett JD, Kent GM et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int.1995 Jan; 47(1): 186-92. PubMed | Google Scholar

  16. Ulasi II, Arodiwe EB, Ijoma CK. Left ventricular hypertrophy in African Black patients with chronic renal failure at first evaluation. Ethn Dis. 2006 Autumn; 16 (4): 859-64. PubMed | Google Scholar

  17. McQuarie EP, Patel RK, Mark PB, Delles C et al. Association between proteinuria and left ventricular mass index: a cardiac MRI study in patients with chronic kidney disease. Nephrol Dial Transp. 2011 Mar; 26(3): 933-938. Google Scholar

  18. Sokolow M, Lyon T. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J. 1949; 37(2): 161-186. PubMed | Google Scholar

  19. Okin PM, Devereux RB, Jern S, Kjeldsen SE et al, LIFE Study Investigators. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA. 2004 Nov; 292(19): 2343-9. PubMed | Google Scholar

  20. Mathew J, Sleight P, Lonn E, Johnstone D et al. Reduction of cardio- vascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation. 2001 Oct 2; 104(14): 1615-21. PubMed | Google Scholar

  21. Ulasi II, Ijoma CK. The Enormity of Chronic Kidney Disease in Nigeria: the Situation in a Teaching Hospital in South-East Nigeria. J Trop Med. 2010 Jun; 2010(2010): 501957. PubMed | Google Scholar

  22. Amoako YA, Laryea DO, Bedu-Addo G, Andoh H, Awuku YA. Clinical and demographic characteristics of chronic kidney disease patients in a tertiary facility in Ghana. The Pan African Medical Journal. 2014; 18:274. PubMed | Google Scholar

  23. Cappuccio FP, Micah FB, Emmett L, Kerry SM et al. Prevalence, detection, management, and control of hypertension in Ashanti, West Africa. Hypertension. 2004 May; 43(5): 1017-22. PubMed | Google Scholar

  24. Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis. 1996 Mar; 27(3): 347-54. PubMed | Google Scholar

  25. Chen SC, Chang J, Liu WC, Tsai Y-C et al. Stepwise Increases in Left Ventricular Mass Index and Decreases in Left Ventricular Ejection Fraction Correspond with the Stages of Chronic Kidney Disease in Diabetes Patients. Exp Diabetes Res. 2012; 2012(2012): 789325. PubMed | Google Scholar

  26. Bregman R, Lemos C, Filho RP, Abensur H et al. Left ventricular hypertrophy in patients with chronic kidney disease under conservative treatment. J Bras Nefrol. 2010; 32(1): 83-88. Google Scholar

  27. Ravera M, Re M, Deferrari L, Vettoretti S, Deferrari G. Importance of blood pressure control in chronic kidney disease. J Am Soc Nephrol. 2006 Apr; 17(4 Suppl 2): S98-103. PubMed | Google Scholar

  28. Campese VM, Mitra N, Sandee D. Hypertension in renal parenchymal disease: why is it so resistant to treatment? Kidney Int. 2006 Mar; 69(6): 967-73. PubMed | Google Scholar

  29. Devereux RB, Dahlof B, Gerdts E, Boman K et al. Regression of hypertensive left ventricular hypertrophy by Losartan compared with Atenolol: the Losartan intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation. 2004 Sep 14; 110(1): 1456-62. PubMed | Google Scholar

  30. Klingbell AU, Schneider M, Martus P, Messerli FH, Schmieder RE. Meta-analysis of effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003 Jul; 115(1): 41-6. Google Scholar

  31. Franklin SS, Khan SA, Whong ND, Larson MG, Levy D. Is pulse pressure useful in predicting risk for coronary heart disease:the Framingham Heart Study. Circulation. 1999; 100(4): 354-60. PubMed | Google Scholar

  32. Paoletti E, Bellino D, Cassottana P, Rolla D, Cannella G. Left ventricular hypertrophy in non-diabetic predialysis CKD. Am J Kid Dis. 2005; 46(2): 320 -327. PubMed | Google Scholar

  33. Lieb W, Mayer B, Stritzke J, Doering A et al. Association of low-grade urinary albumin excretion with left ventricular hypertrophy in the general population: the MONICA/KORA Augsburg Echocardiographic Substudy. Nephrol Dial Transplant. 2006 Oct; 21(10): 2780-7. PubMed | Google Scholar